A Pilot Study to Evaluate the Effects of Vaccinations With HLA-A2-Restricted Glioma Antigen-Peptides With Poly-ICLC for Children With Newly Diagnosed Malignant Brain Stem Gliomas, Non-Brainstem High-Grade Gliomas, Recurrent Low-Grade Gliomas or Recurrent High Grade Gliomas

Trial Profile

A Pilot Study to Evaluate the Effects of Vaccinations With HLA-A2-Restricted Glioma Antigen-Peptides With Poly-ICLC for Children With Newly Diagnosed Malignant Brain Stem Gliomas, Non-Brainstem High-Grade Gliomas, Recurrent Low-Grade Gliomas or Recurrent High Grade Gliomas

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 04 Apr 2017

At a glance

  • Drugs SL 701 (Primary) ; Poly ICLC
  • Indications Anaplastic astrocytoma; Glioblastoma; Glioma; Gliosarcoma
  • Focus Adverse reactions
  • Most Recent Events

    • 29 Mar 2017 Planned primary completion date changed from 1 Feb 2017 to 1 Feb 2019.
    • 29 Mar 2017 Planned primary completion date changed from 1 Feb 2017 to 1 Feb 2019.
    • 08 Jan 2015 Planned primary completion date changed from 1 Feb 2013 to 1 Feb 2017, as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top